NBIX - Neurocrine Biosciences

-

$undefined

N/A

(N/A)

Neurocrine Biosciences NasdaqGS:NBIX Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Location: 12780 El Camino Real, San Diego, CA, 92130, United States | Website: https://www.neurocrine.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

11.79B

Cash

943.5M

Avg Qtr Burn

N/A

Short % of Float

4.12%

Insider Ownership

1.10%

Institutional Own.

98.90%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

INGREZZA (valbenazine) Details
Chorea, Huntington's disease, Dyskinesia

Approved

Quarterly sales

INGREZZA (valbenazine) Details
Huntington's disease, Chorea

Approved

Quarterly sales

INGREZZA (valbenazine) Details
Huntington's disease, Dyskinesia

Approved

Quarterly sales

Phase 3

Data readout

Valbenazine Details
Neurological disorder, Dyskinesia , Dyskinetic cerebral palsy

Phase 3

Data readout

Valbenazine Details
Psychiatric disorder, Schizophrenia

Phase 3

Data readout

Phase 3

Update

NBI-1070770 Details
Major depressive disorder

Phase 2

Data readout

Chronocort® (Efmody) Details
Adrenal Insufficiency

Phase 2

Update

Efmody Details
Congenital adrenal hyperplasia

Phase 2

Update

NBI-921352 Details
Focal Onset Seizures

Phase 2

Update

NBI-1117567 Details
Neurological disorder, Psychiatric disorder

Phase 1

Data readout

NBI-1065890 Details
Neurological disorder

Phase 1

Data readout

NBI-1140675 Details
Neurological disorder, Psychiatric disorder

Phase 1

Data readout

Phase 1

Data readout

NBI-1076986 Details
Parkinson's disease, Dystonia (Blepharospasm)

Phase 1

Data readout

NBI-1065846 Details
Major depressive disorder

Failed

Discontinued

Luvadaxistat Details
Psychiatric disorder, Schizophrenia

Failed

Discontinued